ERBB2 and breast cancer: 115 patients with high-risk clinical stage II/III HER2-positive HR-negative BC who received neratinib in addition to chemotherapy and 78 concurrently randomized controls who received weekly paclitaxel alone were enrolled, and the pCR rate was 56% for the neratinib group and 33% for the control group.